

DATE: May 29, 2007 SHEET 1 of 1

## Form PTO - 1449 (Modified)

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE</b> <b>(Modified) PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)  (37 CFR 1.98 (b))	<b>ATTY. DOCKET NO.</b> 7098.US.P1	<b>SERIAL NO.</b> 10/721,031
	<b>APPLICANT(S)</b> Robert Parsons, et al.	
	<b>FILING DATE</b> 11/24/2003	<b>GROUP</b> 1657

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
RG	A4	5,707,648	01/1998	Yiv, Seang H.			
RG	A5	4,607,023	08/1986	Thibeault et al.			
RG	A6	5,514,670	05/1996	Friedman et al.			
RG	A7	5,444,041	08/1995	Owen et al.			
RG	A8	2005/0136542	06/2005	Todtleben et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

RG	C12	DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS, INC, Nt-proBNP ELISA Quantitative Determination of Nt-proBNP in Biological Fluids (Cat. No. 2852-7), pp. 1-8 (1997).
RG	C13	ALPCO DIAGNOSTICS, Nt-proBNP EIA (Cat. No. 04-B1-20852), pp. 1-5 (October 12, 2004).

EXAMINER

RGUTOMEN

DATE CONSIDERED

5/30/07

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

Patent & Trademark Division

Abbott Laboratories  
One Hundred Abbott Park Road  
Abbott Park, Illinois 60064-6050  
Telecopy: 847-938-7827

**FACSIMILE/TELECOPY COVER SHEET**

DATE: May 29, 2007

TOTAL NUMBER OF PAGES (INCLUDING COVER SHEET): 32

TO: Examiner R. Gitomer (1657)  
United States Patent and Trademark Office

FAX NUMBER: 571-273-0916 (Right Fax)

FROM: Audrey Bartnicki – 847-938-3440

RE: U.S. Serial No.: 10/721,031 (Parsons et al. – 7098USP1)

**MESSAGE:****ATTACHED OFFICIAL FILING FOR ENTRY INTO THE FILE**

1. Transmittal (1 page);
2. Supplemental Information Disclosure Statement (2 pages);
3. Form PTO-1449 (1 page, in duplicate);
4. Copy of Office Action mailed February 27, 2006 in Application No. 11/248,650 and its accompanying Form PTO-892 (Case No. 7098USC1) (13 pages); and
5. Copies of references as cited on PTO-1449 (two "Other Documents") (13 pages).

If you did not receive all the pages or there is a problem with the fax, please call Sherell at (847) 937-6085.

THIS TRANSMISSION IS INTENDED ONLY FOR THE INDIVIDUAL(S) TO WHOM IT IS ADDRESSED. It may contain confidential information, attorney work product, or other privileged material. If you are not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this transmission is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone at (847) 937-6085 and return the transmission to us at the address listed above.

©Abbott Laboratories, 2000. All rights reserved.

## PATENT

## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

Applicant: Parsons, *et al.*

Serial No.: 10/721,031

Filed: November 24, 2003

For: A METHOD OF STABILIZING  
HUMAN NATRIURETIC PEPTIDES  
(formerly "STABLE COMPOSITIONS FOR  
MEASURING HUMAN NATRIURETIC  
PEPTIDES")

Case No.: 7098.US.P1


Group Art No.: 1657

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Examiner: Gitomer, Ralph J.

Certificate of Filing under 37 CFR §1.8(a):  
I hereby certify that this paper (along with any paper  
referred to as being attached or enclosed) is being  
deposited with the United States Patent & Trademark  
Office by facsimile filing on May 29, 2007 as follows:

Examiner R. Gitomer  
Commissioner for Patents  
571-273-0916 (Right Fax)

  
Audrey Bartnicki

TRANSMITTAL LETTER

Dear Sir:


Enclosed herewith for the patent application identified above are the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449, in duplicate;
3. Copy of Office Action mailed February 27, 2006 in Application No. 11/248,650 and its accompanying Form PTO-892 (Case No. 7098USC1); and
4. Copies of references as cited on PTO-1449 (two "Other Documents").

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,  
Parsons, *et al.*

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 938-3440  
Facsimile: (847) 938-7827

  
Audrey L. Bartnicki  
Registration No. 40,499  
Attorney for Applicants

## PATENT

## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

Applicant: Parsons, *et al.*

Serial No.: 10/721,031

Filed: November 24, 2003

For: A METHOD OF STABILIZING  
HUMAN NATRIURETIC PEPTIDES  
(formerly "STABLE COMPOSITIONS FOR  
MEASURING HUMAN NATRIURETIC  
PEPTIDES")

Case No.: 7098.US.P1


Group Art No.: 1657

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Examiner: Gitomer, Ralph J.

**Certificate of Filing under 37 CFR §1.8(a):**  
I hereby certify that this paper (along with any paper  
referred to as being attached or enclosed) is being  
deposited with the United States Patent & Trademark  
Office by facsimile filing on May 29, 2007 as follows:

Examiner R. Gitomer  
Commissioner for Patents  
571-273-0916 (Right Fax)

  
Audrey Bartnicki

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, after the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Documents listed in this Information Disclosure Statement, were first cited in counterpart related US applications. This Information Disclosure Statement is being filed after three months of the mailing date of the communication(s) in the documents were cited.

In particular:

(a) Reference A8 was cited on Form PTO-892 attached to the Office Action mailed April 24, 2006 in Application No. 11/620,475 (Case No. 7098US01).

(b) References A4-A7 and C12-C13 were cited on Form PTO-892 attached to the Office Action mailed February 27, 2006 in Application No. 11/248,650 (Case No. 7098USC1).

(c) Applicants' undersigned counsel became aware on May 25, 2007 on reviewing the subject file and related files 7098US01 and 7098USC1 that the Office Action mailed February 27, 2006 in Application No. 11/248,650 (Case No. 7098USC1) was not listed


on the PAIR database record for Application No. 11/248,650 (Case No. 7098USC1). Thus, a copy of this Office Action and its accompanying Form PTO-892 are filed herewith to become of record and part of the official file of the subject application, and likewise will be timely filed and made of record in the related files 7098US01 and 7098USC1.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,  
Parsons, *et al.*

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 938-3440  
Facsimile: (847) 938-7827

  
Audrey L. Bartnicki  
Registration No. 40/499  
Attorney for Applicants